Affiliation:
1. Rostov State Medical University
2. Medical Center «Professional», Ltd.
3. Lenin Shakhty City Emergency Hospital
Abstract
Introduction. The tactics of managing and treating patients with chronic recurrent bacterial prostatitis (CRBP) in some cases is a difficult-to-treat condition for a practicing urologist. This circumstance occurs because the disease has several predisposing factors, a complex and multifaceted pathogenesis, and certain difficulties in diagnosis and treatment.Objective. To study the effectiveness of recombinant interferon α-2b medications in post-COVID-19 patients with chronic recurrent prostatitis against the background of antibiotic multi-drug resistance of microorganisms verified in prostate secretion.Materials and methods. The treatment of 52 post-COVID-19 patients with CRBP was analyzed, divided into three therapy-dependent groups. Group 1 patients (n = 18) received antibiotic therapy (ABT): Levofloxacin 500 mg q.d. PO for 28 days. Group 2 patients (n = 18) underwent combined therapy: ABT supplemented with recombinant interferon α-2b with an antioxidant complex of vitamins E and C (“Viferon®” rectal suppositories) 3.000.000 IU b.i.d. PR q12h for 28 days. Group 3 patients (n = 16) received monotherapy with recombinant interferon α-2b with an antioxidant complex of vitamins E and C (“Viferon®”rectal suppositories) 3.000.000 IU b.i.d. PR q12h for 28 days. The follow-up period was 6 months with monitoring of clinical and laboratory parameters assessed before treatment, after 1, 3 and 6 months from the start of therapy.Results. Based on the monitoring of the clinical picture and laboratory parameters, after 1 follow-up month, there was a significant decrease in the symptoms of the disease in all study groups. However, after 3 and 6 follow-up months, this trend was observed only in patients of groups 2 and 3 receiving recombinant interferon alfa-2b with an antioxidant complex (vitamins E and C).Conclusions. Strengthening the standard CRBP-therapy with recombinant interferon α-2b with an antioxidant complex of vitamins E and C makes it possible to normalize both clinical and laboratory parameters in most patients.
Publisher
Rostov State Medical University
Reference17 articles.
1. Krupin V.N., Belova A.N., Krupin A.V. Treatment of patients with chronic bacterial prostatitis. Urology Herald. 2019;7(1):26-37. (In Russ.) https://doi.org/10.21886/2308-6424-2019-7-1-26-37
2. Breusoff А.А., Кulchavenya Е.V., Cherednichenko А.G., Stovbun S.V. What does abacterial prostatitits hide? Urology Herald. 2017;5(2):34-41. (In Russ.) https://doi.org/10.21886/2308-6424-2017-5-2-34-41
3. Zaitsev A.V., Pushkar D.Yu., Khodyreva L.A., Dudareva A.A. Bacterial prostatitis and prostatic fibrosis: modern view on the treatment and prophylaxis. Urologiia. 2016;(4):114-121. (In Russ.) EDN: XBKFCD
4. Tkachuk V.N., Tkachuk I.N., Borovec S.Ju. The results of 12-year study of the efficacy of Vitaprost in patients with chronic prostatitis. Urologicheskie vedomosti. 2016;6(4):5-9. (In Russ.) https://doi.org/10.17816/uroved645-9
5. Ibishev H.S., Chernyj A.A., Kogan M.I. Clinical features of a chronic bacterial prostatitis against deficiency of testosterone. Urology Herald. 2013;(1):39-45. (In Russ.) https://doi.org/10.21886/2308-6424-2013-0-1-39-45